152
Participants
Start Date
October 21, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
EMB-01
EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
Beijing cancer Hospital, Beijing
RECRUITING
Nanfang Hospital, Guangzhou
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
West China Hospital, Sichuan University, Chengdu
RECRUITING
The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou
RECRUITING
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Gansu Provincial Hospital, Lanzhou
NOT_YET_RECRUITING
The Affiliated hospital of Qingdao University, Qingdao
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
RECRUITING
First Affiliated Hospital of Zhengzhou University, Zhengzhou
Labcorp Corporation of America Holdings, Inc
INDUSTRY
Shanghai EpimAb Biotherapeutics Co., Ltd.
INDUSTRY